Favorable Results Reported for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study September 24, 2024
FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients Announced September 24, 2024
FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer September 24, 2024
Median OS of 15.6 months in Ph 2 Bria-IMT™ study patients treated in combination with CPI announced September 17, 2024
Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful PFS announced September 17, 2024
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer September 10, 2024
Enrollment Completed in Ph 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting September 3, 2024
Nadunolimab clinical trials in AML/MDA and TNBC to be initiated in Q4 2024 and H2 2025, respectively September 3, 2024
First Patient dosed in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer August 27, 2024
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer August 22, 2024
ENHERTU Type II Variation Application Validated by EMA for Patients with HER2 Low or Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy August 22, 2024
Enrollment of 80mg PK Run-In Cohort in Ph 2 EVANGELINE Trial of (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer Completed July 30, 2024
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations July 23, 2024
Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer Announced July 9, 2024
Type C meeting with FDA supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC) concluded July 1, 2024
FAILED TRIAL: Ph 3 PRESERVE 2 Trial of Trilaciclib Before 1L chemo in mTNBC did Not Achieve Statistical Significance in the Primary Endpoint of OS July 1, 2024
Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer based on CAPItello-291 results June 25, 2024
FAILED TRIAL: CAPItello-290 Ph 3 trial of Truqap (capivasertib) + chemo in locally advanced, inoperable or metastatic TNBC patients with PI3KCA/AKT1/PTEN alterations did not meet the dual primary endpoints of OS improvement June 25, 2024
